NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
- Recruiting
- Jun 3, 2021
- 1 min read
Updated: May 25, 2022
Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06
NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-06 will also be assessed.
Sponsor
Locations
Australia
China
ClinicalTrials.gov Identifier: NCT04735575
Official Title: A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : February 3, 2021
Click here to see details on ClinicalTrials.gov
Biological: EMB-06
EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.
Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06 (Code C179632)
Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06
Anti-BCMA/Anti-CD3 FIT-Ig Bispecific Antibody EMB-06
Anti-BCMA/CD3 Bispecific Antibody EMB-06
BCMAxCD3 Bispecific Antibody EMB-06
EMB 06
EMB-06
EMB06
Fabs-In-Tandem Immunoglobulin Bispecific Antibody EMB-06
Locations
Australia, Queensland
Australia, Victoria
Australia, Western Australia
China, Beijing
China, Shanghai
